The addition of concurrent cisplatin to adjuvant radiation therapy conferred no benefit to women with intermediate-risk, ...

Patanjali’s Renogrit effectively mitigates kidney damage caused by the cancer drug cisplatin, according to a study published ...

Current guidelines lack consensus and rely on lower-quality evidence, according to the author of new research.

However, some patients relapse or present with de novo metastatic disease. For those not recently exposed to platinum-based therapies, the standard of care includes gemcitabine, cisplatin, and the ...

Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...

Updated results from the NIAGARA trial further support perioperative durvalumab and neoadjuvant chemotherapy as a potential new treatment for patients with muscle-invasive bladder cancer, according to ...

Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026.

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical ...

Adjuvant CRT did not improve outcomes over adjuvant RT in patients with intermediate-risk, early-stage cervical cancer after radical hysterectomy.

The study on Renogrit has already been downloaded 2,568 times, highlighting the increasing global interest in Ayurvedic ...

An expert discusses how adjuvant therapy options for high-risk muscle-invasive bladder cancer (MIBC); ypT2-ypT4a or N+) ...